Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1071-1078

  Van Leeuwen, R W F ^a,b   Brundel, D H S ^b   Neef, C ^b   Van Gelder, T ^a   Mathijssen, R H J ^a   Burger, D M ^c   Jansman, F G A ^d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DEVENTER HOSPITAL   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

chemotherapy; oncology; pharmacology; potential drug drug interactions; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; AZITHROMYCIN; CAPECITABINE; CLOPIDOGREL; CORTICOSTEROID; COUMARIN; DASATINIB; DIPYRIDAMOLE; ERYTHROMYCIN; ESOMEPRAZOLE; ETOPOSIDE; GRANISETRON; LEVOFLOXACIN; METHADONE; METHOTREXATE; NILOTINIB; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; PERPHENAZINE; PREDNISOLONE; RISPERIDONE; SOTALOL; SULFAMETHOXAZOLE; TAMOXIFEN; TRIMETHOPRIM; UNINDEXED DRUG;

ADULT; AGED; BLEEDING; BONE MARROW TOXICITY; CANCER PATIENT; CANCER RECURRENCE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG INTERACTION; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOPROTHROMBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SIDE EFFECT; UROGENITAL TRACT CANCER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84875461286     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.48     Document Type: Review

References (44)

1. Drug Interaction Facts. Version 4.0. (2006) Wolters Kluwer Health. Availableat http://www.factsandcomparisons.com (Last consulted on 16 January2013) .
2. Scientific Advisory Board of the Arizona Center for Education and Researchon Therapeutics (CERT) QT Drug Lists. Available at http://www. arizonacert.org (Last consulted on 16 January 2013) .
3. Aisner J (2007) Overview of the changing paradigm in cancer treatment: oralchemotherapy. Am J Health Syst Pharm 64 (suppl 5) : S4-S7.
4. Barrons R (2004) Evaluation of personal digital assistant software for druginteractions. Am J Health Syst Pharm 61: 380-385.
5. Bourré-Tessier J, Haraoui B (2010) Methotrexate drug interactions in thetreatment of rheumatoid arthritis: a systematic review. J Rheumatol 37:1416-1421.
6. Brummett RE (1981) Ototoxicity resulting from combined administration ofpotent diuretics and other agents. Scand Audiol Suppl 14 (suppl) : 215-224.
7. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T (2001) Fatal adversedrug events: the paradox of drug treatment. J Intern Med 250: 327-341.
8. Egger SS, Drewe J, Schlienger RG (2003) Potential drug-drug interactions inthe medication of medical patients at hospital discharge. Eur J ClinPharmacol 58: 773-778.
9. Fisher AA, Davis MW (2002) Serotonin syndrome caused by selectiveserotonin reuptake-inhibitors-metoclopramide interaction. AnnPharmacother 36: 67-71.
10. Chan A, Yap KY, Koh D, Low XH, Cheung YT (2011) from the Onco-Informatics (onco-informatics.com) Group. Electronic database to detectdrug-drug interactions between antidepressants and oral anticancer drugsfrom a cancer center in Singapore: implications to clinicians.Pharmacoepidemiol Drug Saf 20: 939-947.
11. Geppert U, Beindl W, Hawranek T, Hintner H (2003) Drug interactions inclinical practice. A pilot project for quality assurance in prescribing.Hautarzt 54: 53-57.
12. Glintborg B, Andersen SE, Dalhoff K (2005) Drug-drug interactions amongrecently hospitalised patients-frequent but mostly clinically insignificant.Eur J Clin Pharmacol 61: 675-681.
13. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH (2009) NCCN Task Force Report: Bone Health in Cancer Care. J Natl ComprCanc Netw 7 (Suppl 3) : S1-32.
14. Hallberg P, Martén L, Wadelius M (2006) Possible fluconazole-fentanylinteraction-a case report. Eur J Clin Pharmacol 62: 491-492.
15. Hartikainen S, Mäntyselkä P, Louhivuori-Laako K, Enlund H, Sulkava R (2005) Concomitant use of analgesics and psychotropics in homedwellingelderly people-Kuopio 75\+ study. Br J Clin Pharmacol 60:306-310.
16. Houlihan DJ (2004) Serotonin syndrome resulting from coadministration oftramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38: 411-413.
17. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A (2002) Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122-3129.
18. Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC, Lim SW, Salim A (2012) Prevalence of the coprescription of clinically important interacting drugcombinations involving oral anticancer agents in Singapore: aretrospective database study. Clin Ther 34: 1696-1704.
19. Koerber H, Gross WL, Iven H (1994) Do steroids influence low dosemethotrexate pharmacokinetics J Rheumatol 21 1170-1172.
20. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospitaltreatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504-513.
21. Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R (2005) SilverNetwork Home Care Study Group. Psychotropic medications and risk forfalls among community-dwelling frail older people: an observationalstudy. J Gerontol A Biol Sci Med Sci 60: 622-626.
22. Lanza FL (1998) A guideline for the treatment and prevention of NSAIDinducedulcers. Members of the Ad Hoc Committee on PracticeParameters of the American College of Gastroenterology. Am JGastroenterol 93: 2037-2046.
23. Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people:a systematic review and meta-analysis: I. Psychotropic drugs. Am GeriatrSoc 47: 30-39.
24. Lord SR, Menz HB, Tiedemann A (2003) A physiological profile approach tofalls risk assessment and prevention. Phys Ther 83: 237-252.
25. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effectsof St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249.
26. Nakajima M, Genda T, Suehira M, Satoh H, Miki A, Hori S, Sawada Y (2010) Increased anticoagulant activity of warfarin used in combination. CancerChemother Pharmacol 66: 969-972.
27. Official package labeling for Actiq (fentanyl citrate) . Cephalon, Inc.; Salt LakeCity, UT (2007) .Piper JM, Ray WA, Daugherty JR, Griffin MR (1991) Corticosteroid use andpeptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. AnnIntern Med 114: 735-740.
28. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, KrzyzanowskaMK (2007) Potential drug interactions and duplicate prescriptions amongcancer patients. J Natl Cancer Inst 99: 592-600.
29. Ritchie LD, Grant SM (1989) Tamoxifen-warfarin interaction: the Aberdeenhospitals drug file. BMJ 298: 1253.
30. Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat RevCancer 6: 546-558.
31. Seideman P, Müller-Suur R (1993) Renal effects of aspirin and low dosemethotrexate in rheumatoid arthritis. Ann Rheum Dis 52: 613-615.
32. Shah SR, Martin R, Dowell JE, Ussery SM (2010) Comparison of the5-fluorouracil-warfarin and capecitabine-warfarin drug interactions. Pharmacotherapy 30: 1259-1265.
33. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J ClinOncol 28: 2768-2776.
34. Singh G, Rosen Ramey D (1998) NSAID induced gastrointestinalcomplications: the ARAMIS perspective-1997. Arthritis, Rheumatism, andAging Medical Information System. J Rheumatol Suppl 51: 8-16.
35. Tarumi Y, Pereira J, Watanabe S (2002) Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 23:148-153.
36. Tascilar M, de Jong FA, Verweij J, Mathijssen RH (2006) Complementary andalternative medicine during cancer treatment: beyond innocence.Oncologist 11: 732-741.
37. Tinetti ME (2003) Clinical practice. Preventing falls in elderly persons. N EnglJ Med 348: 42-49.
38. Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT (2007) Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 16: 405-411.
39. van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG (2011) Potential drug interactions in cancer therapy:a prevalence study using an advanced screening method. Ann Oncol 22:2334-2341.
40. Verschraagen M, Kedde MA, Hausheer FH, Van der Vijgh WJF (2003) The chemical reactivity of BNP7787 and its metabolite mesna with thecytostatic agent cisplatin: comparsion with the nucleophiled thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer Chemother Pharmacol51: 499-504.
41. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, MarraCA (2009) Meta-analysis of the impact of 9 medication classes on falls inelderly persons. Arch Intern Med 169: 1952-1960.
42. Yancik R, Ries LAG (2000) Aging and cancer in America. Hematol Oncol ClinNorth Am. 14: 17-23.
43. Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oralabsorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50:960-967.
44. Zarychanski R, Wlodarczyk K, Ariano R, Bow E (2006) Pharmacokineticinteraction between methotrexate and piperacillin/tazobactam resulting inprolonged toxic concentrations of methotrexate. J Antimicrob Chemother58: 228-230.